ES2821407T8 - Compuestos de piperidina sustituidos con indol como agentes degradantes de los receptores de estrógenos - Google Patents

Compuestos de piperidina sustituidos con indol como agentes degradantes de los receptores de estrógenos

Info

Publication number
ES2821407T8
ES2821407T8 ES17769483T ES17769483T ES2821407T8 ES 2821407 T8 ES2821407 T8 ES 2821407T8 ES 17769483 T ES17769483 T ES 17769483T ES 17769483 T ES17769483 T ES 17769483T ES 2821407 T8 ES2821407 T8 ES 2821407T8
Authority
ES
Spain
Prior art keywords
estrogen receptor
piperidine compounds
substituted piperidine
degrading agents
indole substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17769483T
Other languages
English (en)
Other versions
ES2821407T3 (es
Inventor
Jianyu Lu
Charles Z Ding
Lihong Hu
Huijun He
Shuhui Chen
Jiaqiang Dong
Tie-Lin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luoxin Healthcare Science And Tech Development Beijing Ltd
Original Assignee
Luoxin Healthcare Science And Tech Development Beijing Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luoxin Healthcare Science And Tech Development Beijing Ltd filed Critical Luoxin Healthcare Science And Tech Development Beijing Ltd
Application granted granted Critical
Publication of ES2821407T3 publication Critical patent/ES2821407T3/es
Publication of ES2821407T8 publication Critical patent/ES2821407T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES17769483T 2016-03-25 2017-03-24 Compuestos de piperidina sustituidos con indol como agentes degradantes de los receptores de estrógenos Active ES2821407T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610180518 2016-03-25
CN201610867918 2016-09-29
PCT/CN2017/078139 WO2017162206A1 (zh) 2016-03-25 2017-03-24 作为雌激素受体降解剂的吲哚并取代哌啶类化合物

Publications (2)

Publication Number Publication Date
ES2821407T3 ES2821407T3 (es) 2021-04-26
ES2821407T8 true ES2821407T8 (es) 2022-02-02

Family

ID=59899253

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17769483T Active ES2821407T3 (es) 2016-03-25 2017-03-24 Compuestos de piperidina sustituidos con indol como agentes degradantes de los receptores de estrógenos

Country Status (12)

Country Link
US (1) US10519143B2 (es)
EP (1) EP3434668B1 (es)
JP (1) JP6790222B2 (es)
KR (1) KR102111792B1 (es)
CN (1) CN108884035B (es)
AU (1) AU2017239348B2 (es)
CA (1) CA3018801C (es)
ES (1) ES2821407T3 (es)
HK (1) HK1256936A1 (es)
RU (1) RU2722441C2 (es)
SG (1) SG11201808363TA (es)
WO (1) WO2017162206A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019057201A1 (zh) * 2017-09-25 2019-03-28 罗欣生物科技(上海)有限公司 一种雌激素受体抑制剂的晶型及其制备方法
AU2019321588A1 (en) 2018-08-17 2021-03-04 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
JP7416540B2 (ja) * 2018-11-28 2024-01-17 羅欣薬業(上海)有限公司 エストロゲン受容体ダウンレギュレーターの塩形態、結晶形及びその製造方法
KR20210105384A (ko) * 2018-12-17 2021-08-26 치아타이 티안큉 파마수티컬 그룹 주식회사 에스트로겐 수용체 길항제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
GB0917571D0 (en) * 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
GB2483736B (en) * 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
NZ630124A (en) 2012-03-20 2016-01-29 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
AU2015228860A1 (en) * 2014-03-13 2016-09-08 F. Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
EP3116497A2 (en) 2014-03-13 2017-01-18 F. Hoffmann-La Roche AG Therapeutic combinations with estrogen receptor modulators

Also Published As

Publication number Publication date
AU2017239348B2 (en) 2020-03-12
KR20180128456A (ko) 2018-12-03
JP6790222B2 (ja) 2020-11-25
CN108884035B (zh) 2020-03-13
EP3434668A4 (en) 2019-08-14
ES2821407T3 (es) 2021-04-26
JP2019512550A (ja) 2019-05-16
SG11201808363TA (en) 2018-10-30
RU2018135203A3 (es) 2020-04-27
CA3018801A1 (en) 2017-09-28
WO2017162206A1 (zh) 2017-09-28
CA3018801C (en) 2020-06-23
CN108884035A (zh) 2018-11-23
KR102111792B1 (ko) 2020-05-18
HK1256936A1 (zh) 2019-10-04
EP3434668B1 (en) 2020-08-26
US10519143B2 (en) 2019-12-31
AU2017239348A1 (en) 2018-11-15
RU2018135203A (ru) 2020-04-27
EP3434668A1 (en) 2019-01-30
US20190106414A1 (en) 2019-04-11
RU2722441C2 (ru) 2020-06-01

Similar Documents

Publication Publication Date Title
MA46188A (fr) Composés indole substitués par pyridyle
EP3512842A4 (en) INDOLDER DERIVATIVES AS A DEGRADOR OF THE ESTROGEN RECEPTOR
IL275356A (en) Modified indole compounds for use as TLR inhibitors
IL261947A (en) History of converted indole compounds as inhibitors of dengue virus replication
IL261948B (en) Transduced indulin derivatives as inhibitors of dengue virus replication
ES2643164T3 (es) Indol 7-sustituido como inhibidores de Mcl-1
DK3313838T3 (da) Polycykliske amidderivater som cdk9-inhibitorer
ES2930298T3 (es) Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona
DK3820873T3 (da) Selektive østrogenreceptornedbrydere
RS62598B1 (sr) N-supstituisani derivati indola kao modulatori receptora pge2
IL275342A (en) Converted indole ether compounds
ES2821407T8 (es) Compuestos de piperidina sustituidos con indol como agentes degradantes de los receptores de estrógenos
DK3798217T3 (da) Piperidin-cxcr7-receptormodulatorer
DK3212637T3 (da) Dopamin-d3-receptorantagonistforbindelser
CL2016002240A1 (es) Derivados de piperidina como antagonista de receptores de orexina
DK3820874T3 (da) Selektive estrogenreceptornedbrydere
DK3265459T3 (da) Amidforbindelser som 5-ht4-receptoragonister
DK3145916T3 (da) Imidazolderivater som formylpeptidreceptormodulatorer
BRPI1008855A2 (pt) derivados de indol como agentes anticâncer
SG11201700655WA (en) Piperazine derivatives as liver x receptor modulators
ZA201804966B (en) 2-oxindole compounds
HUP1800250A2 (en) Substituted (aza)indole derivatives
BRPI1011522A2 (pt) compostos de indol substituídos como moduladores receptor de bradiquinina 1.
HK1243705A1 (zh) 吲哚衍生物
DK3497075T3 (da) Fremgangsmåde til fremstilling af substituerede styren-derivater